Tilray’s Distribution Segment Delivers Double-Digit Growth, but Margins Lag

What happened

Tilray Brands' pharmaceutical distribution segment, CC Pharma, emerged as the company's fastest-growing unit in its latest fiscal year, posting double-digit revenue growth while other segments struggled. The distribution arm, which supplies thousands of European pharmacies, drove overall top-line expansion but contributed relatively thin gross margins of just 13%. This mixed picture aligns with recent filings showing Tilray's total Q2 FY26 net revenue hit a record $218 million, even as the beverage division saw revenue and margins decline sharply. The distribution strength highlights management's bet on European healthcare channels, yet the company remains reliant on non-cash add-backs to post modest adjusted EBITDA of $8.4 million. For investors, the takeaway is that while diversification is paying off on the revenue line, it has yet to translate into meaningful profitability or cash flow generation.

Implication

While the distribution segment’s double-digit growth validates Tilray’s European pharmaceutical strategy, the segment’s thin margins and the overall company’s reliance on non-cash add-backs keep the risk/reward balanced. Until adjusted EBITDA and operating cash flow show sustained improvement alongside top-line expansion, the stock remains a 'show-me' story rather than a buy.

Thesis delta

The distribution segment’s standout growth reinforces Tilray’s European foothold but does little to alter the low-margin, cash-consuming profile. Investors should continue to monitor for tangible EBITDA improvements and cash flow breakeven before adding exposure.